-
5 days ago | 
thereader.com | Ryan Syrek
The “point” of Sinners, a rip-snorting vampire-centric music video, is not that “human beings are the real monsters.” The point of Sinners is a stake, driven through the heart of monsters of all-kinds, fanged or not. It is also that the most important thing in life is having a good time with the ones you love and also not summoning unholy hell-beasts by playing music that is simply too good. You are safest playing bad music.
-
1 week ago | 
thereader.com | Ryan Syrek
In the last week, I saw the movie Warfare, and I learned that someone who used to write here in the film section at The Reader died. Maddeningly, painfully, for the second time in less than a year, I find myself crafting something that is closer to a eulogy than it is a movie review. At least this one isn’t my hot take on an animated family film?
-
2 weeks ago | 
oncologynewscentral.com | Ryan Syrek |Youssef Rddad
The U.S. Food and Drug Administration (FDA) granted full approval to larotrectinib (Vitrakvi) for adults and children with NTRK fusion–positive solid tumors that are metastatic, unresectable, or have no other treatment options, drugmaker Bayer announced in an April 10 news release. Regulators based the latest decision on pooled data from the three single-group studies. These included results from the phase 1 LOXO-TRK-14001 trial, the phase 1/2 SCOUT trial, and the phase 2 NAVIGATE trial.
-
2 weeks ago | 
thereader.com | Ryan Syrek
Casting Michael Fassbender as a militant wife guy who hates liars is certainly a choice when the Wikipedia on his personal life is just right there. Ew.If it helps you endure that knowledge, Black Bag isn’t a sweet love song to marriage so much as a synth-jazz tune about loyalty.
-
2 weeks ago | 
patientpower.info | Ryan Syrek
On March 28, 2025, the U.S. Food and Drug Administration approved neoadjuvant durvalumab (Imfinzi) plus gemcitabine and cisplatin, followed by single-agent adjuvant durvalumab after radical cystectomy, for adults with muscle-invasive bladder cancer (MIBC). The FDA based the approval on results from the randomized, open-label, multicenter, phase 3 NIAGARA trial. The study enrolled 1,063 patients with MIBC who had not received prior systemic therapy and were eligible for radical cystectomy.
-
3 weeks ago | 
oncologynewscentral.com | Youssef Rddad |Ryan Syrek |Marcia Frellick
In March, the U.S. Food and Drug Administration (FDA) granted designations to several key oncology drugs for lung, blood, and pancreatic cancers, among others. Bexmarilimab for Myelodysplastic SyndromesOn March 3, Faron Pharmaceuticals announced that the FDA granted orphan drug designation to bexmarilimab, an investigational immunotherapy, for the treatment of patients with myelodysplastic syndromes (MDS).
-
3 weeks ago | 
thereader.com | Ryan Syrek
If you’re going to cast Paul Rudd, let him be funny. It’s not complicated. You have to actively prevent Paul Rudd from being funny. That is a decision you make. “Stop being funny, Paul Rudd,” you have to say. Paul Rudd is not funny in Death of a Unicorn. Very little is, actually. Will Poulter is funny. That isn’t a joke that Will Poulter is little. He is just the only thing in the movie that works. The rest of it is about as creative, fun, and free-spirited as a unicorn gif on a Tumblr blog.
-
4 weeks ago | 
oncologynewscentral.com | Ryan Syrek |Youssef Rddad
On March 26, 2025, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) for patients aged 12 years and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET) that are not surgically resectable.
-
1 month ago | 
thereader.com | Ryan Syrek
If the start of 2025 hasn’t let y’all know, let me help you out: The future is going to be bad. Real bad. What were once funky fictional postapocalypses have moved from outlandish to landish so fast that if they discover that zombies are real next Tuesday, no one among us will doubt the news. The Assessment isn’t high-concept Armageddon but a bleak soft sci-fi gem that feels like a window into the fast-approaching tomorrow.
-
1 month ago | 
thereader.com | Ryan Syrek
Unsubtle even by TikTok standards, writer/director Mark Anthony Green’s Opus has a hot take on celebrity worship: It is bad. Mind blown yet? Troublingly, the film seems to accidentally file journalism into the naughty bin too, implying that critics and writers are wannabe fame seekers facilitating the problem. Ouch! Personal attack aside, can we maybe give reporters and reviewers just a bit of a break right now? The field is facing a wee bit of a fascism problem.
